Interplay of Tumor Microenvironment and MUC4 in Pancreatic Cancer

$176,545U54FY2015CANIH

University Of Nebraska Medical Center, Omaha NE

Investigators

Linked publications & trials

Paper 38942992 Paper 38853850 Paper 38096060 Paper 37062329 Paper 34180950 Paper 33359791 Paper 33049964 Paper 33024269 Paper 32795414 Paper 32453916 Paper 32036601 Paper 31654638 Paper 31283009 Paper 31025289 Paper 31010242 Paper 30832219 Paper 30830412 Paper 30577767 Paper 30543776 Paper 30111533 Paper 30015157 Paper 29464045 Paper 29256349 Paper 29204701 Paper 28809118 Paper 28697344 Paper 28549596 Paper 28196872 Paper 28122356 Paper 27867838 Paper 27845339 Paper 27838635 Paper 27705923 Paper 27655130 Paper 27605668 Paper 27551331 Paper 27382435 Paper 27267632 Paper 27220889 Paper 27187683 Paper 27185392 Paper 27120458 Paper 27109098 Paper 27026195 Paper 26893480 Paper 26797460 Paper 26771140 Paper 26762229 Paper 26751774 Paper 26742462 Paper 26689992 Paper 26560516 Paper 26527287 Paper 26526617 Paper 26516699 Paper 26510913 Paper 26451384 Paper 26440309 Paper 26364605 Paper 26318196 Paper 26046375 Paper 26044153 Paper 26035354 Paper 25985394 Paper 25906442 Paper 25691062 Paper 25686822 Paper 25634251 Paper 25624117 Paper 25576918 Paper 25551773 Paper 25531332 Paper 25511644 Paper 25506899 Paper 25453266 Paper 25383879 Paper 25263940 Paper 25261375 Paper 25228990 Paper 25223962 Paper 25153488 Paper 25025965 Paper 25003666 Paper 24947474 Paper 24909166 Paper 24747969 Paper 24671186 Paper 24512202 Paper 24479799 Paper 24418575 Paper 24371222 Paper 24278292 Paper 24240113 Paper 24238736 Paper 24204560 Paper 24168188 Paper 24143167 Paper 24077517 Paper 23994756 Paper 23921963

Abstract

Interplay of tumor microenvironment and MUC4 in pancreatic cancer. Clinically, MUC4 mucin is aberrantly overexpressed in pancreatic cancer (PC) tissues and its expression is associated with poor prognosis (1). Studies from our laboratory have conclusively established that MUC4 is involved in enhanced motility, invasiveness and drug resistance of tumor cells in vitro and promotes tumorigenicity and metastasis in vivo (2). MUC4 upregulation is one of the early events in pancreatic cancer as indicated by its upregulation in precursor lesions (3). Our previous studies have demonstrated that MUC4 expression in pancreatic cancer cells in part is regulated by cytokines like IFN- y which are potentially secreted by cells of tumor/inflamed pancreas microenvironment. Inflammation is regarded as a precursor to cancer and in case of pancreatic cancer the increasing evidence supporting the association of pancreatitis to pancreatic cancer risk/development underscores the importance of inflammation in this lethal malignancy. It is thus not surprising that like high MUC4 levels, high levels of pro-inflammatory cytokines (IL-1 & IL-12) in tumor correlates with poor prognosis (4). Given the importance of inflammation and involvement of MUC4 in pancreatic cancer development, and regulation of MUC4 by inflammatory cytokines like IFN- y, the overall objective of this proposal is to understand the modulation of MUC4 expression by tumor microenvironment Another aspect of MUC4 and tumor microenvironment is the ability of MUC4 to interact with and possibly modulate the components of extracellular matrix via the unique domain (NIDO). However, to keep the proposal focused and avoid overlap with our ongoing studies the emphasis of the current application is on the regulation of MUC4 by tumor microenvironment (TME).

View original record on NIH RePORTER →